Consensus on MRD in AML?

Elisabeth M. Paietta

Research output: Contribution to journal › Comment/debate

8 Citations (Scopus)

Abstract

The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.

Original languageEnglish (US)
Pages (from-to)1265-1266
Number of pages2
JournalBlood
Volume131
Issue number12
DOIs
StatePublished - Mar 22 2018

Fingerprint

Residual Neoplasm
Acute Myeloid Leukemia
Guidelines
Blood
Direction compound

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Consensus on MRD in AML? / Paietta, Elisabeth M.

In: Blood, Vol. 131, No. 12, 22.03.2018, p. 1265-1266.

Research output: Contribution to journal › Comment/debate

Paietta, EM 2018, 'Consensus on MRD in AML?', Blood, vol. 131, no. 12, pp. 1265-1266. https://doi.org/10.1182/blood-2018-01-828145
Paietta EM. Consensus on MRD in AML? Blood. 2018 Mar 22;131(12):1265-1266. https://doi.org/10.1182/blood-2018-01-828145
Paietta, Elisabeth M. / Consensus on MRD in AML?. In: Blood. 2018 ; Vol. 131, No. 12. pp. 1265-1266.
@article{b0ef3f911532431fa42a9b363ec4c05f,
title = "Consensus on MRD in AML?",
abstract = "The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.",
author = "Paietta, {Elisabeth M.}",
year = "2018",
month = "3",
day = "22",
doi = "10.1182/blood-2018-01-828145",
language = "English (US)",
volume = "131",
pages = "1265--1266",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Consensus on MRD in AML?

AU - Paietta, Elisabeth M.

PY - 2018/3/22

Y1 - 2018/3/22

N2 - The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.

AB - The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.

UR - http://www.scopus.com/inward/record.url?scp=85047650083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047650083&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-01-828145

DO - 10.1182/blood-2018-01-828145

M3 - Comment/debate

C2 - 29567752

AN - SCOPUS:85047650083

VL - 131

SP - 1265

EP - 1266

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -

Access to Document